cs-121
Familial Chylomicronemia Syndrome (FCS)
CorrectSequence Therapeutics Co., Ltdgene_therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Familial Chylomicronemia Syndrome (FCS) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Plozasiran Arrowhead Pharmaceuticals | Phase 3 | BB |
lcq908 Novartis Pharmaceuticals | Phase 3 | BB |
Volanesorsen Akcea Therapeutics | Phase 3 | B |
VUPANORSEN Akcea Therapeutics | Phase 2 | B |
Slx-4090 University of Texas Southwestern Medical Center | Phase 2 | CCC |
Orlistat University of Texas Southwestern Medical Center | Phase 2 | CCC |
rn0361 Ikaria Bioscience Pty Ltd | Phase 1/2 | CCC |
Olezarsen | D |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →